Glenmark Pharma performance impacted during the quarter due to subdued performance in the India Business. Factors such as divestment of a few non-core brands ( Razel and other dermatology assets), price revision at NLEM, and returns of COVID-related products, has an affect on the India business, resulted in decline of quarterly revenue to INR 8,284 mn (-6.4% YoY, -22.9% QoQ).